404 related articles for article (PubMed ID: 25757684)
1. Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future direction.
Musunuru HB; Loblaw A
Future Oncol; 2015; 11(5):819-31. PubMed ID: 25757684
[TBL] [Abstract][Full Text] [Related]
2. Functional imaging guided stereotactic ablative body radiotherapy (SABR) with focal dose escalation and bladder trigone sparing for intermediate and high-risk prostate cancer: study protocol for phase II safo trial.
Zapatero A; Castro P; Roch M; Carnero PR; Carroceda S; Rosciupchin AES; Hernández SH; Cogorno L; Iturriaga AG; García DB
Radiat Oncol; 2024 May; 19(1):54. PubMed ID: 38702761
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic ablative body radiotherapy for lung cancer.
Franks KN; Jain P; Snee MP
Clin Oncol (R Coll Radiol); 2015 May; 27(5):280-9. PubMed ID: 25746732
[TBL] [Abstract][Full Text] [Related]
4. [Prostate cancer: what treatment techniques for which tumors? Ethical and methodological issues].
de Crevoisier R; Castelli J; Guérif S; Pommier P; Créhange G; Chauvet B; Lagrange JL
Cancer Radiother; 2014 Oct; 18(5-6):369-78. PubMed ID: 25199865
[TBL] [Abstract][Full Text] [Related]
5. Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials.
Connor MJ; Smith A; Miah S; Shah TT; Winkler M; Khoo V; Ahmed HU
Eur Urol Oncol; 2020 Oct; 3(5):582-593. PubMed ID: 32891600
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer--updates of radiobiology, techniques, and clinical outcomes.
Hadziahmetovic M; Loo BW; Timmerman RD; Mayr NA; Wang JZ; Huang Z; Grecula JC; Lo SS
Discov Med; 2010 May; 9(48):411-7. PubMed ID: 20515609
[TBL] [Abstract][Full Text] [Related]
7. A clinical review on extreme hypofractionated stereotactic body radiation therapy for localized prostate cancer using nonrobotic linear accelerators.
Macias VA; Perez-Romasanta LA
Cancer Invest; 2014 Jun; 32(5):191-6. PubMed ID: 24654695
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic Ablative Body Radiotherapy for Intermediate- or High-Risk Prostate Cancer.
Loblaw A
Cancer J; 2020; 26(1):38-42. PubMed ID: 31977383
[TBL] [Abstract][Full Text] [Related]
9. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes.
Loblaw A; Cheung P; D'Alimonte L; Deabreu A; Mamedov A; Zhang L; Tang C; Quon H; Jain S; Pang G; Nam R
Radiother Oncol; 2013 May; 107(2):153-8. PubMed ID: 23647750
[TBL] [Abstract][Full Text] [Related]
10. A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II).
Siva S; Kron T; Bressel M; Haas M; Mai T; Vinod S; Sasso G; Wong W; Le H; Eade T; Hardcastle N; Chesson B; Pham D; Høyer M; Montgomery R; Ball D
BMC Cancer; 2016 Mar; 16():183. PubMed ID: 26944262
[TBL] [Abstract][Full Text] [Related]
11. CyberKnife Stereotactic Ablative Radiotherapy as an Option of Treatment for Patients With Prostate Cancer Having Oligometastatic Lymph Nodes: Single-Center Study Outcome Evaluation.
Napieralska A; Miszczyk L; Stąpór-Fudzińska M
Technol Cancer Res Treat; 2016 Oct; 15(5):661-73. PubMed ID: 26208835
[TBL] [Abstract][Full Text] [Related]
12. Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trial.
Ong WL; Cheung P; Chung H; Chu W; Detsky J; Liu S; Morton G; Szumacher E; Tseng CL; Vesprini D; Davidson M; Ravi A; McGuffin M; Zhang L; Mamedov A; Deabreu A; Kulasingham-Poon M; Loblaw A
Radiother Oncol; 2023 Apr; 181():109503. PubMed ID: 36754232
[TBL] [Abstract][Full Text] [Related]
13. SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer.
Fredman E; Icht O; Moore A; Bragilovski D; Kindler J; Golan S; Limon D
BMC Cancer; 2024 Apr; 24(1):431. PubMed ID: 38589860
[TBL] [Abstract][Full Text] [Related]
14. Serious complications associated with stereotactic ablative radiotherapy and strategies to mitigate the risk.
Lo SS; Sahgal A; Chang EL; Mayr NA; Teh BS; Huang Z; Schefter TE; Yao M; Machtay M; Slotman BJ; Timmerman RD
Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):378-87. PubMed ID: 23375484
[TBL] [Abstract][Full Text] [Related]
15. Role of the technical aspects of hypofractionated radiation therapy treatment of prostate cancer: a review.
Clemente S; Nigro R; Oliviero C; Marchioni C; Esposito M; Giglioli FR; Mancosu P; Marino C; Russo S; Stasi M; Strigari L; Veronese I; Landoni V
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):182-95. PubMed ID: 25835624
[TBL] [Abstract][Full Text] [Related]
16. Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: From chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases.
Saluja R; Cheung P; Zukotynski K; Emmenegger U
Urol Oncol; 2016 May; 34(5):225-32. PubMed ID: 27008982
[TBL] [Abstract][Full Text] [Related]
17. Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function.
Senger C; Conti A; Kluge A; Pasemann D; Kufeld M; Acker G; Lukas M; Grün A; Kalinauskaite G; Budach V; Waiser J; Stromberger C
BMC Urol; 2019 Oct; 19(1):96. PubMed ID: 31638979
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiotherapy for prostate cancer.
Henderson DR; Tree AC; van As NJ
Clin Oncol (R Coll Radiol); 2015 May; 27(5):270-9. PubMed ID: 25707911
[TBL] [Abstract][Full Text] [Related]
19. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
[TBL] [Abstract][Full Text] [Related]
20. Dose escalation for prostate stereotactic ablative radiotherapy (SABR): Late outcomes from two prospective clinical trials.
Alayed Y; Cheung P; Pang G; Mamedov A; D'Alimonte L; Deabreu A; Commisso K; Commisso A; Zhang L; Quon HC; Musunuru HB; Helou J; Loblaw DA
Radiother Oncol; 2018 May; 127(2):213-218. PubMed ID: 29588072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
